Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
441-460 of 2,120 trials

Non-Small Cell Lung Cancer: Fianlimab and Cemiplimab with Chemotherapy

We are studying if adding Fianlimab to Cemiplimab and chemotherapy is safer and more effective for adults with early-stage non-small cell lung cancer that can be surgically removed. This trial will help us understand the best treatment options for these patients.

Resectable Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)16-20 visitsStandard MedicinesCost ReimbursementPartially RemoteOncology

Duchenne Muscular Dystrophy: GNT0004 Gene Therapy

We are testing a new gene therapy for boys with Duchenne Muscular Dystrophy who can walk. The study aims to find the right dose and evaluate the therapy's safety and effectiveness compared to a placebo.

Duchenne Muscular DystrophySafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineNeurologyPediatrics

Combination Therapies for Advanced Esophageal Cancer

We are studying new treatment combinations for patients with advanced esophageal cancer who have already been treated with PD-1/PD-L1 therapies. The aim is to evaluate their safety and how well they work in shrinking tumors and improving survival.

Advanced Esophageal Squamous Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteOncology

Colon Cancer Treatment: Neo-Adjuvant Chemotherapy for Seniors

We are studying whether a 6-week chemotherapy treatment before surgery helps older adults with resectable colon cancer live longer and stay disease-free. This trial aims to personalize treatment for patients aged 70 and older.

Colon Cancer>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Acute Pancreatitis: Omega-3 Fatty Acid Infusion

We are studying whether early intravenous omega-3 fatty acids can help reduce organ failure and mortality in patients with acute pancreatitis. This trial compares the effects of omega-3s to standard medical care.

Severe Acute Pancreatitis6-12 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesGastroenterologyInternal Medicine

Multiple Myeloma: Innovative Treatment Approaches

We are studying new methods to monitor multiple myeloma in patients who have not yet been treated. This trial compares different treatment combinations, including a stem cell transplant, to see which is more effective.

Multiple Myeloma6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Type 1 Diabetes: New Cell Therapy for Children

We are studying a new treatment combining cell therapy and an antibody for children with early-stage type 1 diabetes. The goal is to see if this approach can help delay the onset of diabetes symptoms.

Prediabetes>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesEndocrinologyInfectious DiseasesPediatrics

Heart Health: Adenosine Dose Study

We are investigating how different doses of adenosine affect blood flow in the heart for healthy individuals and patients with coronary artery disease. This study aims to understand if the response varies based on health status.

Chronic Ischemic Heart DiseaseMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Osteoarthritis in the Thumb: Comparing Treatments

We are studying whether steroid injections are more effective than saline injections and occupational therapy for painful thumb osteoarthritis. The goal is to improve pain, function, and overall quality of life.

Osteoarthritis of the Thumb>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesOrthopedics and TraumatologyRheumatology

Acute Myeloid Leukemia: MP0533 Treatment Study

We are testing a new drug, MP0533, for patients with acute myeloid leukemia or myelodysplastic syndrome. The study aims to evaluate its safety and how well it may work against these blood cancers.

Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)Safety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

High-Risk Retroperitoneal Sarcoma: Chemotherapy Before Surgery

We are testing whether chemotherapy before surgery improves outcomes for patients with high-risk retroperitoneal sarcoma. This study compares the effects of preoperative chemotherapy to surgery alone.

Dedifferentiated LiposarcomaLeiomyosarcoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Coronary Disease: Tirzepatide Study

We are exploring whether tirzepatide can improve heart health by changing plaque composition and blood flow in people with obesity and coronary artery disease. This study compares tirzepatide to a placebo to assess its effects.

Overweight and Obesity1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Diffuse Large B-Cell Lymphoma: Epcoritamab with R-CHOP

We are studying whether adding Epcoritamab to standard R-CHOP treatment helps people with newly diagnosed Diffuse Large B-Cell Lymphoma live longer without disease progression. This trial compares the new combination to R-CHOP alone.

Diffuse Large B-Cell Lymphoma1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Ofatumumab in Breast Milk: A Study for Lactating Women with MS

We are examining how much ofatumumab is found in the breast milk of mothers with relapsing multiple sclerosis. This research will help us understand the safety and effects on breastfeeding infants.

Multiple Sclerosis Relapse1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsNeurology

Advanced NSCLC: EXL-01 with Nivolumab

We are studying the combination of EXL-01 and nivolumab for patients with advanced non-small cell lung cancer who have not responded to prior immunotherapy. The trial aims to evaluate how well this combination works and its safety.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology

Triple Negative Breast Cancer: Capecitabine and Pembrolizumab Study

We are studying the effects of capecitabine combined with pembrolizumab in patients with triple negative breast cancer after surgery and chemotherapy. This trial aims to see if this combination improves survival rates compared to standard treatments.

Triple Negative Breast Cancer6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Dostarlimab for Advanced Cancer with dMMR/MSI

We are studying whether the immunotherapy dostarlimab can help patients with advanced non-colorectal and non-endometrial cancers live longer compared to standard treatments. This trial focuses on those with specific genetic markers in their tumors.

dMMR/MSI Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Advanced Melanoma: IMC-F106C Plus Nivolumab

We are studying a new treatment combination for people with previously untreated advanced melanoma. The goal is to see if it helps patients live longer and have better outcomes compared to standard treatment.

Advanced Melanoma1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Metastatic Non-Small Cell Lung Cancer: ONC-392 vs. Docetaxel

We are studying a new treatment, ONC-392, to see if it helps patients with metastatic non-small cell lung cancer who have progressed on immunotherapy. The goal is to compare its effectiveness and safety against the standard treatment, docetaxel.

Metastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Perianal Crohn’s Disease: FAPi-PET Imaging Study

We are exploring whether a new imaging method can help visualize and measure healing in fistulas for patients with perianal Crohn’s disease. This study may also help predict how well treatments are working.

Crohn's DiseaseFistulizing Crohn's Disease≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal Medicine